CASP3 and chronic myelogenous leukemia, BCR-ABL1 positive: Accordingly, DIF-3 exerted only a marginal induction of caspase-3 activity compared with the effects of imatinib, which is the most frequently used compound to treat CML and is also known to be a potent inducer of apoptosis in K562 cells [33] (Figure 1E).